XML 59 R38.htm IDEA: XBRL DOCUMENT v3.25.4
Financial Risk Management (Tables)
12 Months Ended
Dec. 31, 2025
Financial Risk Management  
Schedule of undiscounted liabilities into relevant maturity groupings.

​

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​

Within

  ​ ​ ​

Between 1 

  ​ ​ ​

Between 2 

  ​ ​ ​

​

​

​

1 year  

​

and 2 years  

​

and 5 years  

​

Over 5 years  

​

​

(€ in thousands)

At December 31, 2025

 

  ​

 

  ​

 

  ​

 

  ​

Borrowings

 

5,162

​

—

​

—

​

—

Lease liabilities

​

1,978

​

2,374

​

7,121

​

1,187

Trade payables and other payables

 

8,238

​

—

​

—

​

—

Total

 

15,378

 

2,374

 

7,121

 

1,187

​

​

​

​

​

​

​

​

​

At December 31, 2024

 

  ​

 

  ​

 

  ​

 

  ​

Borrowings

 

4,872

​

—

​

—

​

—

Lease liabilities

​

2,114

​

2,306

​

6,917

​

3,459

Trade payables and other payables

 

10,343

​

—

​

—

 

—

Total

 

17,329

 

2,306

 

6,917

 

3,459

Schedule of how fair value of financial assets and liabilities is measured

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Relationship and

​

​

​

​

​

​

sensitivity of

​

  ​ ​ ​

Valuation technique

  ​ ​ ​

Significant unobservable

  ​ ​ ​

Significant unobservable

Financial liabilities

​

and key inputs

​

inputs

​

inputs to fair value

​

 

  ​

 

  ​

 

​

Investment in Kamal Therapeutics, Inc (previously known as Phoenicis Therapeutics, Inc)

​

Market comparison technique: The valuation model is based on market multiples derived from quoted prices of companies comparable to the investee, adjusted for the effect of the non-marketability of the equity securities, and the result of the investee. The estimate is adjusted for the net debt of the investee.

​

Adjusted market-multiple

​

The estimated fair value would increase (decrease) if the adjusted market-multiple were higher (lower).

​

​

​

​

​

​

​

Investment in Yarrow Biotechnology, Inc.

​

Market comparison technique: The valuation model is based on market multiples derived from quoted prices of companies comparable to the investee, adjusted for the effect of the non-marketability of the equity securities, and the result of the investee. The estimate is adjusted for the net debt of the investee.

​

Adjusted market-multiple

​

The estimated fair value would increase (decrease) if the adjusted market-multiple were higher (lower).

​

​

​

​

​

​

​

Warrants and conversion options

 

Black-Scholes model. The following variables were taken into consideration: current underlying price of the Company's shares, options strike price, expected life, historical volatility of ProQR share returns over a period equal to the expected life, risk-free rate: based on the US Treasury yield curve rates per the valuation date (interpolated) for the expected life.

​

Not applicable

​

Not applicable